AGIOAgios Pharmaceuticals, Inc.
Price
-16%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growing in the filings, the market undecided.
We are a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities, collaborating to develop and deliver innovative medicines with the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve.
In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Agios Pharmaceuticals, Inc. (AGIO) reported revenue of $45M in Q2 2026 (quarter ended Jun 30, 2026), up 259% from the same quarter a year earlier. That came with a gross margin of 93% and net loss of $101M. For the full year FY2025, revenue was $54M (+48% year on year) and net income −$413M. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 30, 2026Agios Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jun 18, 2026At the 2026 Annual Meeting of Stockholders of Agios Pharmaceuticals, Inc. (the “Company”) held on June 18, 2026 (the “Annual Meeting”), the Company’s stockholders approved an amendment (the “2023 Plan Amendment”) to the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan (the “Current Plan”)Director or officer change · Form 8-K
- Apr 29, 2026Agios Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.